Walleye Capital’s Immunic IMUX Stock Holding History

Walleye Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,415	Closed	-$329K	–	3391
2022 Q3	$329K	Buy	+10,415	New	+$436K	0.01%	1764
2021 Q4	–	Sell	-1,989	Closed	-$176K	–	2195
2021 Q3	$176K	Buy	+1,989	New	+$196K	0.01%	1223
2018 Q3	$7K	Buy	+68	New	+$178K	﹤0.01%	306

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Walleye Capital's IMUX Position: Q4 2022 in Review

Walleye Capital sold out of Immunic (IMUX) in Q4 2022, closing a stake of 10,415 shares — an estimated $329K sold.

Walleye Capital first reported a position in IMUX in Q3 2018 and held it in 3 quarters. The position peaked at $329K in Q3 2022. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2022.

Walleye Capital reported no remaining Immunic position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 10,415 Immunic shares in Q4 2022, an estimated $329K.
Walleye Capital first reported a position in Immunic in Q3 2018 and held it in 3 quarters.
Walleye Capital's Immunic position peaked at $329K in Q3 2022.
58 funds tracked by Wall St. Rank held Immunic as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.